Lupin receives USFDA approval for generic Flagyl Tablets

13 Sep 2017 Evaluate

Lupin has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of G.D. Searle LLC’s Flagyl Tablets, 250 mg and 500 mg. Flagyl Tablets had US sales of $44.1 million as per IMS MAT June 2017.

The company’s Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of G.D. Searle LLC’s Flagyl Tablets, 250 mg and 500 mg. It is indicated in the treatment of wide variety of infections which are caused by particular types of bacteria and other infectious organisms.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2114.10 33.75 (1.62%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×